Clinical risk factors and association of hyperhomocysteinemia with diabetic retinopathy in Iranian type 2 diabetes patients. A cross-sectional study from Shiraz, Southern Iran

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 2, Issue 3, 2008, Pages 192-201

  Golbahar, Jamal ^a,b   Rahimi, Mansour ^b   Tabei, Mohammad Bagger ^b   Aminzadeh, Mohammad Amin ^b  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetic retinopathy; Hyperhomocysteinemia; Risk factors

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IRAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; PREVALENCE; PRIORITY JOURNAL; RETINA ANGIOGRAPHY; RISK FACTOR;

EID: 47649091112     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2008.05.001     Document Type: Article

References (45)

1. Zimmet P., Alberti K., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
2. Congdon N.G., Friedman D.S., and Lietman T. Important causes of visual impairment in the world today. JAMA 290 (2003) 2057-2060
3. Klein R., et al. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 107 (1989) 244-249
4. Kristinsson J.K., Stefánsson E., Jónasson F., Gíslason I., and Björnsson S. Screening for eye disease in type 2 diabetes mellitus. Acta Ophthalmol Scand 72 (1994) 341-346
5. Henricsson M., Groop L., and Heijl A. Progression of retinopathy is related to glycaemic control even in patients with mild diabetes mellitus. Acta Ophthalmol Scand 74 (1996) 528-532
6. Stratton I.M., Kohner E.M., Aldington S.J., Turner R.C., Holman R.R., Manley S.E., et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 44 (2001) 156-163
7. UK Prospective Diabetes Study (UKPDS) Group. Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 18 (2001) 178-184
8. Varma R., et al. Prevalence of diabetic retinopathy in adult Latinos. Ophthalmology 111 (2004) 1298-1306
9. Klein R., Klein B.E., Moss S.E., and Cruickshanks K.J. XIV Ten-year incidence and progression of diabetic retinopathy, The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol 112 (1994) 1217-1228
10. Chico A., Perez A., Cordoba A., Arcelús R., Carreras G., de Leiva A., et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease?. Diabetologia 41 (1998) 684-693
11. Chiarelli F., Pomilio M., Mohn A., Tumini S., Vanelli M., Morgese G., et al. homocysteine levels during fasting and after methionine loading in adolescents with diabetic retinopathy and nephropathy. J Pediatr 137 (2000) 386-392
12. Vaccaro O., Perna A.F., Mancini F.P., Iovine C., Cuomo V., Sacco M., et al. Plasma homocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis 10 (2000) 297-304
13. Hoogeveen E.K., Kostense P.J., Eysink P.E., Polak B.C., Beks P.J., Jakobs C., et al. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med 160 (2000) 2984-2990
14. Emoto M., Kanda H., Shoji T., Kawagishi T., Komatsu M., Mori K., et al. Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 24 (2001) 533-538
15. Agardh E., Hultberg B., and Agardh C.D. Severe retinopathy in type 1 diabetic patients is not related to the level of plasma homocysteine. Scand J Clin Lab Invest 60 (2000) 169-174
16. Soedamah-Muthu S.S., Chaturvedi N., Teerlink T., Idzior-Walus B., Fuller J.H., Stehouwer C.D., et al. Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross-sectional nested case-control study, Eurodiab Prospective Complications Study Group. J Intern Med 258 (2005) 450-459
17. Hultberg B., Agardh E., Andersson A., Brattström L., Isaksson A., Israelsson B., et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 51 (1991) 277-282
18. Alfthan G., Aro A., and Gey K.F. Plasma homocysteine and cardiovascular disease mortality. Lancet (1997) 349-397
19. Diabetes mellitus. Report of a WHO Study Group: Tech. Rep. Ser. 727; 1985, pp. 1-113.
20. Golbahar J., Aminzadeh M.A., Al-Shboul Q.M., Kassab S., and Rezaian G.R. Association of methylenetetrahydrofolate reductase (C677T) polymorphism with hyperuricemia. Nutr Metab Cardiovasc Dis 17 (2007) 462-467
21. Golbahar J., Rezaian G., and Bararpour H. Distribution of plasma total homocysteine concentrations in the healthy Iranians. Clin Biochem 37 (2004) 149-151
22. Nygard O., Vollset S.E., Refsum H., Stensvold I., Tverdal A., Nordrehaug J.E., et al. Total plasma homocysteine and cardiovascular risk profile, The Hordaland Homocysteine Study. JAMA 274 (1995) 1526-1533
23. Wollesen F., Brattsröm L., Refsum H., Ueland P.M., Berglund L., and Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 55 (1999) 1028-1035
24. Salardi S., Cacciari E., Sassi S., Grossi G., Mainetti B., Dalla Casa C., et al. Homocysteinemia, serum folate and vitamin B12 in very young patients with diabetes mellitus type 1. J Pediatr Endocrinol Metab 13 (2000) 1621-1627
25. Clarkson P., Celermajer D.S., Donald A.E., Sampson M., Sorensen K.E., Adams M., et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 28 (1996) 573-579
26. Harris M.I., Klein R., Cowie C.C., Rowland M., and Byrd-Holt D.D. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in Non-Hispanic whites with type 2 diabetes?. Diabetes Care 21 (1998) 1230-1235
27. Klein R., Klein B.E., Moss S.E., Davis M.D., and DeMets D.L. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years, The Wisconsin Epidemiologic Study of Diabetic Retinopathy III. Arch Ophthalmol 102 (1984) 527-532
28. Wong T.Y., Klein R., Islam F.M., Cotch M.F., Folsom A.R., Klein B.E., et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 141 (2006) 446-455
29. Santos K.G., Tschiedel B., Schneider J.R., Souto K.E., and Roisenberg I. Prevalence of retinopathy in Caucasian type 2 diabetic patients from the South of Brazil and relationship with clinical and metabolic factors. Braz J Med Biol Res 38 (2005) 221-225
30. West S.K., Munoz B., Klein R., Broman A.T., Sanchez R., Rodriguez J., et al. Risk factors for type II diabetes and diabetic retinopathy in a Mexican-American population: Proyecto VER. Am J Ophthalmol 134 (2002) 390-398
31. Klein R., Klein B.E., Moss S.E., Davis M.D., and DeMets D.L. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260 (1988) 2864-2871
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
33. Looker H.C., Krakoff J., Knowler W.C., Bennett P.H., Klein R., and Hanson R.L. Longitudinal studies of incidence and progression of diabetic retinopathy assessed by retinal photography in Pima Indians. Diabetes Care 26 (2003) 320-326
34. Stratton I.M., Cull C.A., Adler A.I., Matthews D.R., Neil H.A., and Holman R.R. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 49 (2006) 1761-1769
35. Gillow J.T., Gibson J.M., and Dodson P.M. Hypertension and diabetic retinopathy-what's the story?. Br J Ophthalmol 83 (1999) 1083-1087
36. Klein R., and Klein B.E. Blood pressure control and diabetic retinopathy. Br J Ophthalmol 86 (2002) 365-367
37. Kohner E.M. Diabetic retinopathy. Br Med Bull 45 (1989) 148-173
38. Estacio R.O., Jeffers B.W., Gifford N., and Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23 (2000) B54-B64
39. Agardh C.D., Agardh E., Andersson A., and Hultberg B. Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 54 (1994) 637-641
40. Starkebaum G., and Harlan J.M. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77 (1986) 1370-1376
41. Chen C., Conklin B.S., Ren Z., and Zhong D.S. Homocysteine decreases endothelium-dependent vasorelaxation in porcine arteries. J Surg Res 10 (2002) 222-230
42. Hofmann M.A., Kohl B., Zumbach M.S., Borcea V., Bierhaus A., Henkels M., et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 21 (1998) 841-848
43. Moore P., El-sherbeny A., Roon P., Schoenlein P.V., Ganapathy V., and Smith S.B. Apoptotic cell death in the mouse retinal ganglion cell layer is induced in vivo by the excitatory amino acid homocysteine. Exp Eye Res 73 (2001) 45-57
44. Sobczak A.J. The effects of tobacco smoke on the homocysteine level-a risk factor of atherosclerosis. Addict Biol 8 (2003) 147-158
45. Hu R., Zhang X.X., Wang W.Q., Lau C.P., and Tse H.F. Smoking, homocysteine and degree of arteriolar retinopathy. Atherosclerosis 183 (2005) 95-100